The Flt3-based fate-mapping strategy overcomes the limitations of prior approaches by the continuously renewed expression of the reporter in circulating monocytes in a mouse model with slower plaque growth that mimics the clinical evolution of pathology in AD. The gene discussed is FLT3; the disease is Alzheimer disease.